Medicus Pharma
Holding Companies & Conglomerates · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
300 Conshohocken State Rd Ste 200, Consh...Phone Number
(610) 636-0184Website
www.medicuspharma.comRevenue
-Stock Symbol
MDCXIndustry
ZI Rank: 3
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
5
5
3
3
About Medicus Pharma
Medicus Pharma Ltd is a clinical stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials. Through the company's diverse experience and extensive industry network, the company is building Medicus into a leading pharmaceutical holding company, committed to delivering better treatment outcomes and alleviate pain and suffering. Utilizing a thesis driven collaborative process, the company identify, acquire and advance relatively de-risked clinical stage assets through clinical development and commercialization.Explore more
Medicus Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Medicus Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Medicus Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Medicus Pharma had a recent Job posting/layoffs
Product Launch: Get notified when Medicus Pharma launches new products
Congratulate Masked Content for being promoted to Masked Content at Medicus Pharma
Check if Medicus Pharma has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Medicus Pharma has new funding data
Check out if Medicus Pharma is spiking on competitors!
Earning: See what the market has to say on Medicus Pharma recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Medicus Pharma as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Medicus Pharma is experiencing very low activity levels compared to other companies in the Holding Companies & Conglomerates sector.
What does this means?
Medicus Pharma is drawing exceptional interest within the Holding Companies & Conglomerates industry, suggesting notable developments or strong market momentum, learn more about Medicus Pharma.
Medicus Pharma financials insights
Gather financial insights about Medicus Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Debt
$8M
2026
Debt
$22M
Medicus Pharma Tech Stack
A closer look at the technologies used by Medicus Pharma
See more technologies
Most Recent Scoops
Funding
Funding
Promotion
Executive Move
Executive Moves, Promotion
Left Company
Executive Move
Executive Moves, Left Company
Funding
Funding
Lateral Move
Executive Move
Executive Moves, Lateral Move
Medicus Pharma News & Media
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
Randomized Phase 2a PRECISION-E2 study designed to evaluate a predefined panel of genes to advance personalized medicine in women's health Randomized Phase 2a PRECISION-E2 study designed to evaluate a predefined panel of genes to advance personalized medicine in women's healthMedicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
SKNJCT-005 registrational clinical study protocol strengthened through planned implementation of FDA recommendations, including combined clinical and histological clearance endpoints and extended patient follow-up SKNJCT-005 registrational clinical study protocol strengthened through planned implementation of FDA recommendations, including combined clinical and histological clearance endpoints and extended patient follow-upMedicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
Regulatory and ethical-review milestones advance a capital-efficient Phase 2 study expected to enroll ~126 patients versus ~390 under the previously disclosed development plan Regulatory and ethical-review milestones advance a capital-efficient Phase 2 study expected to enroll ~126 patients versus ~390 under the previously disclosed development planIs Medicus Pharma Ltd. (MDCX) Stock Gaining Momentum With Innovative Skin Cancer Treatment Technology?
We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Medicus Pharma Ltd. (NASDAQ:MDCX) is one of the best low-priced pharma stocks on this list. TheFly reported on June 15 that MDCX announced the filing of a Rare Pediatric Disease Designation request with the U.S. Food and Drug Administration for SkinJect, its […]
Read more news
Top Holding Companies & Conglomerates Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Medicus Pharma
Sign Up For FreeTo access detailed company insights
Medicus Pharma Ltd is a clinical stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials. Through the company's diverse experience and extensive industry network, the company is building Medicus into a leading pharmaceutical holding company,... Read More
